MYRIAD GENETICS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements
MYRIAD GENETICS, INC. (MYGN) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements of $5.80 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-28.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements · last filed 2025-02-28
- MYRIAD GENETICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2024-12-31 was $0.00.
- MYRIAD GENETICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2024-09-30 was $0.00.
- MYRIAD GENETICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2021-12-31 was $0.00.
- MYRIAD GENETICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- MYRIAD GENETICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2024 was $5.80M.
- MYRIAD GENETICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- MYRIAD GENETICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2022 was $3.00M, a 9.09% decline from fiscal 2021.
- MYRIAD GENETICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2021 was $3.30M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $0.00 derived: sum of 2 quarters · filed 2025-02-28 | $5.80M 10-K · filed 2025-02-28 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $5.80M 10-Q · filed 2024-11-08 | ||
| 2024-06-30 | $5.80M 10-Q · filed 2024-08-07 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-02-28 | |||
| 2022-12-31 | $3.00M 10-K · filed 2025-02-28 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $0.00 derived: sum of 2 quarters · filed 2024-02-28 | $0.00 derived: sum of 3 quarters · filed 2024-02-28 | $3.30M 10-K · filed 2024-02-28 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $0.00 derived: sum of 2 quarters · filed 2021-11-04 | $3.30M 10-Q · filed 2021-11-04 | $3.30M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $3.30M 10-Q · filed 2021-08-04 | $3.30M derived: sum of 3 quarters · filed 2023-03-01 | $3.40M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $3.30M 10-Q · filed 2021-05-05 | $3.30M derived: sum of 2 quarters · filed 2023-03-01 | $3.40M derived: sum of 3 quarters · filed 2023-03-01 | $3.40M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $0.00 derived: 10-K 6 month − 10-Q 3 month · filed 2023-03-01 | $100.00K 10-K · filed 2023-03-01 | $100.00K derived: sum of 3 quarters · filed 2023-03-01 | $100.00K derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-09-30 | $100.00K 10-Q · filed 2020-11-09 | $100.00K derived: sum of 2 quarters · filed 2023-03-01 | $100.00K derived: sum of 3 quarters · filed 2023-03-01 | $700.00K derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $0.00 derived: sum of 2 quarters · filed 2023-03-01 | $600.00K derived: sum of 3 quarters · filed 2023-03-01 | $3.90M 10-K · filed 2023-03-01 |
| 2020-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-05-06 | $600.00K derived: sum of 2 quarters · filed 2020-05-06 | $3.90M 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $600.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-02-07 | $3.90M 10-Q · filed 2020-02-07 | ||
| 2019-09-30 | $3.30M 10-Q · filed 2019-11-06 | |||
| 2019-06-30 | $0.00 10-K · filed 2022-02-25 | |||
| 2018-06-30 | $1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2018-08-24 | $65.10M 10-K · filed 2018-08-24 | ||
| 2018-03-31 | $63.20M 10-Q · filed 2018-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |